| A systematic review of religious beliefs about major end-of-life issues in the five major world religions R Chakraborty, AR El-Jawahri, MR Litzow, KL Syrjala, AD Parnes, ... Palliative & supportive care 15 (5), 609-622, 2017 | 169 | 2017 |
| Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category E Muchtar, A Dispenzieri, SK Kumar, RP Ketterling, D Dingli, MQ Lacy, ... Leukemia 31 (7), 1562-1569, 2017 | 135 | 2017 |
| Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ... Leukemia 32 (10), 2240-2249, 2018 | 97 | 2018 |
| Autologous stem cell transplant for multiple myeloma patients 70 years or older E Muchtar, D Dingli, S Kumar, FK Buadi, A Dispenzieri, SR Hayman, ... Bone marrow transplantation 51 (11), 1449-1455, 2016 | 84 | 2016 |
| Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities R Chakraborty, S Sidana, GL Shah, M Scordo, BK Hamilton, NS Majhail Biology of Blood and Marrow Transplantation 25 (5), e155-e162, 2019 | 83 | 2019 |
| Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition E Muchtar, A Dispenzieri, MQ Lacy, FK Buadi, P Kapoor, SR Hayman, ... Annals of medicine 49 (7), 545-551, 2017 | 78 | 2017 |
| Systemic immunoglobulin light chain amyloidosis–associated myopathy: presentation, diagnostic pitfalls, and outcome E Muchtar, D Derudas, M Mauermann, T Liewluck, A Dispenzieri, ... Mayo Clinic Proceedings 91 (10), 1354-1361, 2016 | 66 | 2016 |
| Treatment of relapsed multiple myeloma: Evidence-based recommendations C Durer, S Durer, S Lee, R Chakraborty, MN Malik, A Rafae, MA Zar, ... Blood Reviews 39, 100616, 2020 | 63 | 2020 |
| The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment E Muchtar, D Jevremovic, A Dispenzieri, D Dingli, FK Buadi, MQ Lacy, ... Blood, The Journal of the American Society of Hematology 129 (1), 82-87, 2017 | 63 | 2017 |
| Health-related quality of life after autologous stem cell transplantation for multiple myeloma R Chakraborty, BK Hamilton, SK Hashmi, SK Kumar, NS Majhail Biology of Blood and Marrow Transplantation 24 (8), 1546-1553, 2018 | 59 | 2018 |
| Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era R Chakraborty, E Muchtar, SK Kumar, D Jevremovic, FK Buadi, D Dingli, ... Blood cancer journal 6 (12), e512-e512, 2016 | 56 | 2016 |
| Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics R Chakraborty, E Muchtar, SK Kumar, D Jevremovic, FK Buadi, D Dingli, ... Biology of Blood and Marrow Transplantation 23 (4), 598-605, 2017 | 55 | 2017 |
| Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies R Chakraborty, BT Hill, A Majeed, NS Majhail Transplantation and cellular therapy 27 (3), 222-229, 2021 | 49 | 2021 |
| Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review R Chakraborty, L Cannella, F Cottone, F Efficace The Lancet Haematology 7 (12), e892-e901, 2020 | 45 | 2020 |
| Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis R Chakraborty, I Bin Riaz, SU Malik, N Marneni, A Mejia Garcia, F Anwer, ... Cancer 126 (8), 1640-1650, 2020 | 42 | 2020 |
| Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront … R Chakraborty, E Muchtar, SK Kumar, D Jevremovic, FK Buadi, D Dingli, ... haematologica 102 (8), 1439, 2017 | 42 | 2017 |
| The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents R Chakraborty, E Muchtar, S Kumar, FK Buadi, D Dingli, A Dispenzieri, ... Bone marrow transplantation 52 (1), 34-40, 2017 | 42 | 2017 |
| Treatment and disease‐related complications in multiple myeloma: implications for survivorship R Chakraborty, NS Majhail American journal of hematology 95 (6), 672-690, 2020 | 41 | 2020 |
| Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma M Mohan, R Chakraborty, S Bal, A Nellore, M Baljevic, A D'Souza, ... British Journal of Haematology 203 (5), 736-746, 2023 | 40 | 2023 |
| Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival GMA Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S ... Leukemia, 2016 | 40* | 2016 |
